经鼻持续正压通气+肺表面活性物质治疗早产儿呼吸窘迫综合征疗效观察

Observation on BiCPAP combined with pulmonary surfactant in the treatment of premature infants with respiratory distress syndrome

目的探讨经鼻持续正压通气BiCPAP+肺表面活性物质治疗早产儿呼吸窘迫综合征疗效。方法将2014年10月～2017年10月在我院接受治疗的100例呼吸窘迫综合征早产儿作为主要研究对象,运用随机数字表法分组,每组50例。对照组患儿采用BiCPAP治疗,观察组患儿采用BiCPAP+肺表面活性物质治疗,比较两组的治疗效果。结果通过比较两组患儿的治疗成功率,发现观察组患儿的治疗成功率明显高于对照组患儿,两组相比差异有统计学意义(P <0.05);观察组患儿的呼吸困难缓解时间明显短于对照组,组间比较差异有统计学意义(P <0.05);治疗后,两组患儿的PaO_2、PaCO_2较治疗前相比均有显著改善,且观察组的血气指标改善情况明显优于对照组,差异有统计学意义(P <0.05);两组患儿的并发症发生率比较,差异无统计学意义(P> 0.05)。结论在早产儿呼吸窘迫综合征的临床治疗上,采用BiCPAP联合肺表面活性物质的治疗方式可获得理想效果,治疗成功率更高,患儿的血气指标改善情况较好,且安全性高,故值得进一步推广应用。

Objective To expliore the effect of BiCPAP(nasal continuous positive airway pressure) combined with pulmonary surfactant on premature infants with respiratory distress syndrome. Methods 100 premature infants with respiratory distress syndrome who were treated in our hospital from October 2014 to October 2017 were selected as the main research objects.They were divided into two groups with 50 cases in each group according to digital random method.Infants in the control group were treated with BiCPAP,while infants in the observation group were treated with BiCPAP combined with pulmonary surfactant.The therapeutic effects of the two groups were compared. Results The success rate of treatment in the observation group was significantly higher than that in the control group and there was significant difference between the two groups(P < 0.05).The time to relieve dyspnea in the observation group was significantly shorter than that in the control group,and there was a significant difference between the groups(P < 0.05).After treatment,PaO2 and PaCO2 of premature infants in two groups were both improved.The improvement of blood gas index in the observation group was significantly better than that in the control group and the difference was statistically significant(P < 0.05).There was no significant difference in the incidence of complications between the two groups(P > 0.05). Conclusion BiCPAP combined with pulmonary surfactant in the clinical treatment of premature infants with respiratory distress syndrome can achieve ideal effects.The success rate of treatment is higher and the improvement of blood gas index is better.In addition,it has high safety,which is worthy of further promotion and application.